



Announcement

Recent Research on Liver Diseases in Singapore:

Antonio Iannetti,

prof. Antonio Iannetti www.iannetti.it
www.gastroenterologoiannetti.com antonio@iannetti.it fax +39 06.233.297.473 cell +39 335.6935321

Market Value:

Recent Research on Liver Diseases in Singapore:

Singapore—Liver cancer remains a major problem in healthcare globally, being the second most common cause of cancer-related death globally. Previous studies showed that this disease, especially its predominant form hepatocellular carcinoma (HCC), exhibits substantial heterogeneity. However, efforts to categorize HCC more precisely have been limited by an inability to integrate data from various sources into a single classification system.

Singapore University centered research group has made a major advance in this field by combining data on mutations, gene expression patterns, and immunological status to shed light on the variation among cases of HCC. The study, recently reported in the journal EBioMedicine, reveals that there are actually three distinct types of this disease, which should help in predicting the prognosis of individual patients and treating them more effectively.

Global Hepatology and Liver Diseases market (2018-2025)

The global Infectious Diseases and therapy on Liver market is expected to reach US\$ 4,056.4 Mn in 2025 from US\$ 2,011.2 Mn in 2017. The market is estimated to grow with a CAGR of 8.1% from 2018-2025.

The growth of the Liver Cancer therapy market is primarily attributed to the increase in the number of therapies launched in the market. The development of new drugs is thus expected to drive the growth of Liver diseases therapy mainly Liver Cancer market. For instance, in October 2015, the FDA approved the Onivyde drug by Merrimack Pharmaceuticals, Inc. as a part of treatment regimen for advanced cancer. Some common side effects associated with chemotherapy drugs include diarrhea and abdominal cramping, fatigue, loss of appetite, change in food taste and others. Cancer cells that are rapidly growing are killed by chemotherapy drugs.


Anwen Rosella

Program Manager

Liver Diseases 2020

E:liverdiseases@asiameets.com

P: +44 203 769 0972



■ North America ■ Europe ■ Asia Pacific ■ Latin America ■ MEA

Liver Disease Treatment Market Report has been published by Allied Market Research, forecasts that the global market is expected to reach \$19,536 million by 2022, registering a CAGR of 11.72% during the period 2016 - 2022. The antiviral drug segment held a major share of the total market in 2015 and is expected to maintain its lead throughout the forecast period. This is attributed to the high incidences of virus-infected liver diseases including Hepatitis, which are genetically, immunologically, pathologically related. However, corticosteroid drug segment registered fastest growing segment during the forecast period.

The factors driving the liver disease treatment market are rapidly changing lifestyle patterns such as increasing consumption of alcohol, and unhealthy diets; and the increasing prevalence of liver diseases.

Key findings of liver Disease Treatment Market:

- The Corticosteroids drug is projected to be the fastest growing segment, registering a CAGR of 16.49% during the forecast period
- North America is expected to lead the market throughout 2022 and is projected to grow at a CAGR of 11.89%, during 2016 and 2022
- Asia-Pacific is expected to grow with a CAGR of around 12.51%, due to the increasing prevalence of liver diseases and increasing R&D investments in this region
- liver diseases including Hepatitis, immunologically, pathologically related.